Life Fest 2010: Celebrating a Decade of Life
Life Fest 2010: Celebrating a decade of life. It has been a remarkable decade for the GIST community as scientific discovery, medical treatment and drug development have put GIST
Cross-continental fun at the LRG office!
There has been some cross-continental fun as of late at the LRG Office. Estelle Lecointe, French cancer advocacy poster girl, founder of Ensemble Contre le GIST, and all-around pretty groovy person stopped by LRG headquarters in [...]
LRG in the News: Poster & Abstracts, oh my!
The LRG keeps popping up in the science community. Recently, the National Institutes of Health (NIH) as part of the Consortium for Pediatric & GIST Research (of which, LRG is a part) submitted a poster [...]
GIST Supporters ‘Show The Love’ for Texas Marathoner
GIST supporters showed their love for Texas marathoner Kate Poss. Keep reading for more on this inspirational story.
December 2009 clinical trials update
Here is a clinical trials update from December 2009 written by Jim Hughes United States RAD001 in combination with CP- 751,871 in patients with advanced sarcomas and other malignant neoplasms (NCT00927966) An mTOR inhibitor (RAD001) and [...]
GIST Member Story – Jerry Call
You sit alone in a dreary doctor’s office; evidence of his medical expertise and importance adorn the walls. Maybe you sit there with a loved one, equally as scared and unprepared as you. The doctor hands you a verdict that says your time is up. Well now what do you do?
REGISTER Study Open in Australia, New Zealand and South Korea
An interesting Phase 2 REGISTER study is ongoing and actively recruiting at 15 sites in Australia. Two sites in New Zealand and two sites in South Korea are also planned.
Cherished mother & farm girl passes away
Neva Hatten Hageman, passed away Wednesday (08/12/09) at The Ambassador in Nebraska City. She was born to George and Ruth (Kempf) Calkins, at home on the family farm, Northwest of McCook, in Hayes County. Those [...]
Analysis of an observational registry of gastrointestinal stromal tumor (GIST) patients
This poster reported the latest data from the GIST ReGISTry, an online database of GIST patient statistics maintained by a group of American and Canadian GIST specialists and supported by Novartis Pharmaceuticals.
Phase 1 evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV
Four GIST patients have entered this Phase 1 trial of PI3K inhibitor SF1126.